Physician profile
Solomon I Paley
NPI 1952409831
$136,498.67
in general payments reported to CMS, 2019-2025
66 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,374 · 2020: $7,126 · 2021: $20K · 2022: $21K · 2023: $44K · 2024: $16K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Food and Beverage: $10K · Travel and Lodging: $8,881 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,100.00 |
| Food and Beverage | $10,089.91 |
| Travel and Lodging | $8,881.46 |
| Education | $120.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $119,107.80 | 2019-2025 | Repatha, Repatha, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $2,864.35 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $2,047.49 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,865.53 | 2021-2025 | |
| Lilly USA, LLC | $1,609.93 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,286.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $912.80 | 2021-2025 | |
| Allergan, INC. | $661.63 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $648.77 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $518.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.40 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $383.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $346.59 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $336.25 | 2019-2022 | |
| Esperion Therapeutics, INC. | $278.75 | 2020-2023 | Nexletol |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solomon Paley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.